| Symbol | LENZ |
|---|---|
| Name | LENZ THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 201 HASKINS WAY,SUITE 210, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 484-0886 |
| Fax | — |
| — | |
| Website | https://www.lenz-tx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001815776 |
| Description | LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. Additional info from NASDAQ: |
(30% Negative) LENZ THERAPEUTICS, INC. (LENZ) Reports Q2 2026 Financial Results
Read moreNew Form ARS - LENZ Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001815776-26-000029 <b>Size:</b> 38 MB
Read moreNew Form DEFA14A - LENZ Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001815776-26-000028 <b>Size:</b> 334 KB
Read moreNew Form DEF 14A - LENZ Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001815776-26-000026 <b>Size:</b> 1 MB
Read moreLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
Read moreNew Form SCHEDULE 13G - LENZ Therapeutics, Inc. <b>Filed:</b> 2026-04-08 <b>AccNo:</b> 0001642575-26-000004 <b>Size:</b> 22 KB
Read moreDirector George Jeffrey P. 🟢 acquired 5.6K shares of LENZ Therapeutics, Inc. (LENZ) at $8.92 Transaction Date: Mar 27, 2026 | Filing ID: 000003
Read moreDirector Schimmelpennink Evert B. 🟢 acquired 28.1K shares of LENZ Therapeutics, Inc. (LENZ) at $8.95 Transaction Date: Mar 27, 2026 | Filing ID: 000004
Read moreChevallard Daniel R. 🟢 acquired 7.5K shares of LENZ Therapeutics, Inc. (LENZ) at $8.57 Transaction Date: Mar 27, 2026 | Filing ID: 000004
Read moreNew Form S-8 - LENZ Therapeutics, Inc. <b>Filed:</b> 2026-03-24 <b>AccNo:</b> 0001815776-26-000013 <b>Size:</b> 741 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06270030 | Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solut… | Phase1 | Presbyopia | Completed | 2024-03-04 | 2024-04-10 | ClinicalTrials.gov |
| NCT06045299 | Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia | Phase3 | Presbyopia | Completed | 2023-09-27 | 2025-01-27 | ClinicalTrials.gov |
| NCT05936489 | Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in… | Phase1 | Eye Diseases | Completed | 2023-07-06 | 2023-10-03 | ClinicalTrials.gov |
| NCT05728944 | Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia | Phase3 | Presbyopia | Completed | 2023-03-06 | 2024-01-24 | ClinicalTrials.gov |
| NCT05753189 | Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subje… | Phase3 | Presbyopia | Completed | 2023-02-21 | 2024-02-09 | ClinicalTrials.gov |
| NCT05656027 | Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatm… | Phase3 | Presbyopia | Completed | 2022-12-19 | 2024-01-25 | ClinicalTrials.gov |
| NCT05431543 | Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidin… | Phase2 | Presbyopia | Completed | 2022-08-06 | 2022-12-14 | ClinicalTrials.gov |
| NCT05294328 | Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) a… | Phase2 | Presbyopia | Completed | 2022-05-05 | 2022-09-10 | ClinicalTrials.gov |
| NCT03201562 | A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100… | Phase2 | Presbyopia | Completed | 2017-04-30 | 2018-05-20 | ClinicalTrials.gov |
| NCT02554396 | Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to M… | Phase2 | Presbyopia | Completed | 2015-09-01 | 2015-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Placebo | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT02554396 |
| PRX-100 | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT02554396 |
| Vehicle | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Aceclidine | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Aceclidine+tropicamide combination | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Aceclidine | Other | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Aceclidine + Brimonidine | Other | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Placebo (Vehicle) ophthalmic solution | Other | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| LNZ100 (Aceclidine) ophthalmic solution | Other | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| LNZ101 (Aceclidine /Brimonidine) ophthalmic solution | Other | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| Vehicle proprietary ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Aceclidine ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Vehicle Proprietary Ophthalmic Solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine Ophthalmic Solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Placebo | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Placebo (Vehicle) ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Vehicle | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Brimonidine | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Aceclidine+Brimonidine combination ophthalmic solution | Other | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| LNZ100 (Aceclidine) ophthalmic solution | DRUG | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| LNZ101 (Aceclidine /Brimonidine) ophthalmic solution | DRUG | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| Placebo (Vehicle) ophthalmic solution | DRUG | Phase PHASE1 | Presbyopia | COMPLETED | NCT06270030 |
| Aceclidine + Brimonidine | DRUG | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Aceclidine Ophthalmic Solution | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| Brimonidine | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05656027 |
| Vehicle proprietary ophthalmic solution | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT05431543 |
| Vehicle Proprietary Ophthalmic Solution | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT05294328 |
| Aceclidine ophthalmic solution | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Aceclidine+Brimonidine combination ophthalmic solution | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT06045299 |
| Vehicle | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05728944 |
| Aceclidine | DRUG | Phase PHASE1 | Eye Diseases | COMPLETED | NCT05936489 |
| Aceclidine+tropicamide combination | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT03201562 |
| Placebo | DRUG | Phase PHASE3 | Presbyopia | COMPLETED | NCT05753189 |
| PRX-100 | DRUG | Phase PHASE2 | Presbyopia | COMPLETED | NCT02554396 |